Evidence map›Paper›PMID 40948342›Full record

ArticleCancer medicine2025

Cost-Effectiveness Analysis of First-Line Chemotherapy for Metastatic Pancreatic Cancer in Japan.

Yuriko Sasahara, Yuki Takumoto, Tatsunori Murata, Manabu Akazawa, Hiroto Narimatsu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuriko SasaharaDepartment of Medical Oncology, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Yuki TakumotoDepartment of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9191-3494
Tatsunori MurataCRECON Medical Assessment Inc, Tokyo, Japan.
Manabu AkazawaDepartment of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.
Hiroto NarimatsuCancer Prevention and Cancer Control Division, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.ORCID https://orcid.org/0000-0002-0383-4911

Funding

Japan Society for the Promotion of Science 19H03874
6 · The paper itself

Abstract

backgroundsPancreatic cancer is a highly aggressive disease with limited treatment options. The combination of tegafur, gimeracil, and oteracil (S-1) has emerged as a promising treatment approach in Japan. However, the economic implications of S-1 compared to other chemotherapy regimens have not been fully explored.

methodsThis cost-effectiveness analysis study evaluated the economic position of S-1 relative to fluorouracil+leucovorin+irinotecan+oxaliplatin (FFX), gemcitabine+Nab-paclitaxel (GnP), and gemcitabine (GEM) for the treatment of distant metastatic pancreatic cancer in Japan. Incremental cost-effectiveness ratios were calculated using quality-adjusted life years (QALYs) as the measure of effectiveness.

resultsS-1 demonstrated the lowest incremental cost-effectiveness ratio compared to FFX, GnP, and GEM, indicating that it offers the most value for the cost. The total cost per QALY for S-1 was significantly lower than the other regimens. Additionally, S-1 was associated with favourable safety and convenience profiles.

conclusionThe findings of this study suggest that S-1 is a cost-effective and promising treatment option for distant metastatic pancreatic cancer in Japan. Its favourable economic profile, combined with its safety and convenience advantages, makes it a viable choice for patients and healthcare providers.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCost-Benefit AnalysisPancreatic NeoplasmsAgedAlbuminsCost-Effectiveness AnalysisDeoxycytidineDrug CombinationsFemaleFluorouracilGemcitabineHumansIrinotecanJapanLeucovorinMale130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineDrug CombinationsFluorouracilGemcitabineIrinotecanLeucovorinOxaliplatinOxonic AcidPaclitaxelS 1 (combination)TegafurICERincremental cost‐effectivenessQALYS‐1safety

Identifiers

PMID40948342
PMCPMC12434479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.